Selective Delivery of a Therapeutic Gene for Treatment of Head and Neck Squamous Cell Carcinoma Using Human Neural Stem Cells

Seong Keun Kwon1* · Seung U Kim2,3 · Jae-Jun Song1 · Chang Gun Cho1 · Seok-Won Park1

1Department of Otorhinolaryngology-Head and Neck Surgery, Dongguk University Ilsan Hospital, Goyang; 2Institute for Regenerative Medicine, Gachon University Gil Hospital, Incheon, Korea; 3Division of Neurology, Department of Medicine, UBC Hospital, University of British Columbia, Vancouver, BC, Canada

INTRODUCTION

Despite recent advances in ablative surgical resection, radiotherapy, and chemotherapy, recurrence and metastasis remains sig-

Objectives. Based on studies of the extensive tropism of neural stem cells (NSCs) toward malignant brain tumor, we hypothesized that NSCs could also target head and neck squamous cell carcinoma (HNSCC) and could be used as a cellular therapeutic delivery system.

Methods. To apply this strategy to the treatment of HNSCC, we used a human NSC line expressing cytosine deaminase (HB1.F3-CD), an enzyme that converts 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU), an anticancer agent. HB1.F3-CD in combination with 5-FC were cocultured with the HNSCC (SNU-1041) to examine the cytotoxicity on target tumor cells in vitro. For in vivo studies, an HNSCC mouse model was created by subcutaneous implantation of human HNSCC cells into athymic nude mice. HB1.F3-CD cells were injected into mice using tumoral, peritumoral, or intravenous injections, followed by systemic 5-FC administration.

Results. In vitro, the HB1.F3-CD cells significantly inhibited the growth of an HNSCC cell line in the presence of the 5-FC. Independent of the method of injection, the HB1.F3-CD cells migrated to the HNSCC tumor, causing a significant reduction in tumor volume. In comparison to 5-FU administration, HB1.F3-CD cell injection followed by 5-FC administration reduced systemic toxicity, but achieved the same level of therapeutic efficacy.

Conclusion. Transplantation of human NSCs that express the suicide enzyme cytosine deaminase combined with systemic administration of the prodrug 5-FC may be an effective regimen for the treatment of HNSCC.

Keywords. Head and neck neoplasms, Neural stem cells, Tropism, Cytosine deaminase, Molecular targeted therapy

5-Fluorouracil (5-FU) is a major anti-tumor chemotherapeutic agent that has been widely used in the treatment of head and neck cancers alone or in combination with other chemotherapeutic agents [2]. However, this widely-used anticancer agent has several limitations, including serious side effects, such as pancytopenia and diarrhea, anorexia, nausea, and taste changes, and high dose levels are required to achieve a response. High
systemic toxicity of 5-FU could possibly be circumvented by introducing directed expression of bacterial and/or yeast cytosine deaminase (CD), an enzyme that converts the far less toxic substrate 5-fluorocytosine (5-FC) into 5-FU [3]. 5-FU is capable of non-facilitated diffusion in and out of cells, resulting in a significant bystander effect caused by CD/5-FC treatment [4].

Successful gene therapy technology relies on the delivery of the therapeutic product to the appropriate target cells. Introduction of the transgene of interest into stem cell types poses an attractive cell-based delivery strategy [5]. The discovery of the inherent tumor-tropic properties of neural stem cells (NSCs) could serve as a novel adjuvant strategy to complement current head and neck cancer treatments. Recent studies have shown that NSCs can be used to target therapeutic genes to brain tumors, including malignant glioma [6] and melanoma brain metastases [7]. We have expanded on these investigations to determine whether NSCs are also capable of targeting head and neck carcinomas in an animal xenograft model. Therapeutic proof-of-concept studies were performed using CD-expressing NSCs and systemic 5-FC prodrug administration.

**MATERIALS AND METHODS**

**Cell culture**

HB1.F3 (F3) is an immortalized human NSC line. It was derived from human fetal brain (ventricular zone) at 15 weeks of gestation and immortalized using an amphotropic, replication-incompetent retroviral vector containing v-myec [8-11]. This is a well-established and well-characterized NSC line that is multipotent, migratory, and non-tumorigenic in vivo [8-15]. F3 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 2 mmol/L L-glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL amphotericin B (Invitrogen, Grand Island, NY, USA).

The human head and neck cancer cell line SNU-1041 was maintained in DMEM containing 10% FBS, 100 units/mL penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL amphotericin B (Invitrogen).

**Engineering of the human NSC line HB1.F3-CD**

The clonal HB1.F3-CD (F3-CD) cell line was derived from the parental F3 line. An expression plasmid encoding *Escherichia coli* CD was constructed using the retroviral pBabePuro backbone and the 1.5 kb CD cDNA. Vectors were packaged by co-transfection of pA317 cells with the CD-Puro plasmid and the MV12 envelope-coding plasmid. CD-Puro retroviral supernatant was used for multiple infections of F3 cells. Transduced F3-CD cells were selected in the presence of 3 μg/mL puromycin (Invitrogen) over 4 weeks. Successful transduction of the F3-CD cells was confirmed by reverse transcription PCR (rt-PCR) using the following primer pair: sense, 5’GGCGCAGTCACCGC-CAGCCACACCCAGGC-3’ and antisense, 5’GTGGTAATC-GATGGCTTCTGGCTGC-3’.

**In vitro therapeutic efficacy of F3-CD**

F3 cells, F3-CD cells, SNU-1041 cells (3×10^6 cells per well), and F3-CD cells (10^6 per well) co-cultured with SNU-1041 cells (2×10^6 per well) were plated in 96-well plates in triplicate and incubated overnight at 37°C. Culture medium was replaced with medium containing 0-2.5 mg/mL 5-FU after 24 hours. Four days later, plates were subjected to a standard MTT assay. Results were expressed as the percentage of proliferation and were normalized to proliferation of cells in culture medium with no 5-FC.

**Labeling of F3-CD cells with ferumoxides**

Ferumoxides, a superparamagnetic iron oxide contrast agent (Feridex, Berlex, Wayne, NJ, USA), was used for magnetic labeling of F3-CD. Feridex is FDA-approved for clinical use in liver imaging and is commercially available [16]. Ferumoxides acts by reducing the transverse relaxation time (T2) on T2-weighted magnetic resonance imaging scans, causing labeled cells to appear as areas of reduced signal intensity.

For labeling experiments, ferumoxides (25 mg/mL) and polyl-lysine (PLL, Sigma, St. Louis, MO, USA; 0.75 mg/mL) were mixed together with media and incubated at room temperature for 60 minutes [17,18]. PLL acts as a transfection reagent by binding the dextran-coated ferumoxides nano-particles via electrostatic interactions [19] and facilitating uptake into cells through membrane destabilization [20]. The F3-CD cells were then incubated for 24 hours at 37°C to allow uptake of ferumoxides into the cells. Labeled F3-CD cells were identified as blue dots using Prussian blue staining.

**In vivo visualization of migration of F3-CD cells to the tumor site**

Six-week-old female athymic nude mice (BALB/c-nu/nu) were used for in vivo experiments in accordance with institutional guidelines under approved protocols. A suspension of 1×10^6 SNU-1041 cancer cells in 100 μL phosphate-buffered saline (PBS) was administered by subcutaneous injection (s.c.) at the posterior neck of nine animals. On day 7, 1×10^6 F3-CD cells tagged with Feridex were injected into the tumor-bearing mice using one of three different methods: at the tumor center (n=3), 1.5 cm from the tumor margin (peritumoral injection, n=3), or intravenously (i.v.) in the tail vein (n=3). To detect F3-CD cells located near tumor tissues, animals were sacrificed on day 14, and Prussian blue staining was performed on tissues from the brain, lung, liver, spleen, heart, and tumor.

**In vivo therapeutic efficacy of F3-CD cell-mediated treatment**

Six-week-old female athymic nude mice (BALB/c-nu/nu) were used. Cancer cells were administered as a suspension of 1×10^6
SNU-1041 cells in 100 μL PBS s.c. at the posterior neck in 50 animals. On day 7, 1 × 10⁶ F3-CD cells in 100 μL PBS were injected by one of three different methods: at the tumor center (group 1, n = 10), 1.5 cm from the tumor margin (group 2, n = 10), or i.v. in the tail vein (groups 3-5, n = 30).

Beginning at day 14, all animals in groups 1, 2, and 3 were treated with 500 mg/kg/d 5-FC diluted in PBS, delivered by intraperitoneal injection (i.p.) in two rounds of five consecutive days with a 2-day break where indicated. Group 4 (control group) animals were treated only with PBS, and group 5 animals were treated with 20 mg/kg/d 5-FU i.p., instead of 5-FC.

Tumors were measured using calipers, and tumor volume was calculated according to the following formula: volume = (height × width²)/2 [21]. Animals were weighed daily. At the end point of the experiment, animals were sacrificed and tumors were excised. Results were evaluated as mean tumor volume or weight ± standard error (SE).

Statistics
Values were expressed as mean ± SE or as mean percentage of control ± SE. Significant differences were determined using the Mann-Whitney U-test. A P < 0.05 was deemed to indicate statistical significance.

RESULTS

Confirmation of CD production in F3-CD cells
Expression of the CD transcript in F3-CD cells was confirmed by rt-PCR. Results showed that the CD transcript was expressed only in F3-CD cells, not in the parental F3 cell line (Fig. 1).

In vitro therapeutic efficacy of F3-CD cell-mediated therapy
To confirm the “bystander effect” caused by release of 5-FU from F3-CD cells, cell viability studies were performed. Growth of 5-FC-treated, F3-CD cells, and SNU-1041 cells co-cultured with F3-CD cells was significantly inhibited in a dose-dependent manner, but growth of F3 cells or SNU-1041 cells alone was unaffected by 5-FC treatment (Fig. 2). SNU-1041 cells cultured with F3-CD cells exhibited no growth inhibition in the absence of 5-FC treatment. These observations indicate that F3-CD cells...
can convert sufficient amounts of 5-FC to 5-FU, which diffuses locally to effectively kill SNU-1041 cells in vitro.

**In vivo** visualization of migration of F3-CD cells to tumors
F3-CD cells were identified as blue dots stained with Prussian blue and were found in tissues taken from tumors, regardless of the method of injection. Most of the stained cells were found surrounding the tumor border. The density of stem cells was highest in the tumor center injection group and lowest in the tail vein injection group (Fig. 3A-C).

Tissues from the brain (Fig. 3D), heart (Fig. 3E), kidney (Fig. 3F), lung, liver (Fig. 3H), and spleen (Fig. 3I) were negative for Prussian blue staining in the tumor center injection group and the peritumoral injection group. Tissue from the lung (Fig. 3G) exhibited minimal staining in the tail vein injection group. Other tissues from the tail vein injection group were negative for Prussian blue staining, indicating an absence of F3-CD cells in these tissues.

**In vivo** therapeutic efficacy of F3-CD cell-mediated treatment
**In vivo** studies showed a significant reduction in tumor volume in 5-FC-treated animals (groups 1-3) in comparison with control animals treated with PBS (group 4; \(P < 0.01\)) (Fig. 4). Use of different injection methods did not lead to significant changes in tumor volume. No significant difference in tumor volume was observed between 5-FC-treated animals injected with F3-CD cells (groups 1-3) and animals treated with 5-FU (group 5).

**Side effects of treatment**
There was no significant difference in weight between animals treated with 5-FC and animals treated with PBS. Animals treat-

---

Fig. 3. Tumor homing capabilities of HB1.F3-CD (F3-CD) cells (Prussian blue staining, \(\times 40\)). F3-CDs were labeled with Feridex and injected into the tail vein (A), subcutaneously 1.5 cm from the tumor injection site (B), or at the tumor center (C) on 7 day after tumor cell inoculation. Mice were sacrificed on day 14, and Prussian blue staining was performed. F3-CDs were found primarily at the tumor border (white arrowheads). F3-CDs were not observed in tissues from brain (D), heart (E), kidney (F), liver (H), or spleen (I). F3-CDs were observed in lung tissue (G, black arrowhead) at a very low frequency.
Fig. 5. Antitumor effects of therapeutic HB1.F3-CD (F3-CD) cells in the presence of 5-fluorocytosine (5-FC) in vivo. (A) Timeline for experiment. (B) Representative mice from control (group 4) and 5-FC treated (group 3) groups. (C) The F3-CD/5-FC regimen caused an inhibitory effect on tumor growth in all experimental animals, irrespective of stem cell injection method. Significant decreases in tumor growth occurred in groups 1, 2, and 3 in comparison to the control group (group 4). In comparison with the conventional treatment group (group 5), there was no significant difference in tumor volume. s.c., subcutaneous injection; PBS, phosphate-buffered saline; i.v., intravenous injection. *P<0.05. **P<0.01, Mann-Whitney U-test.

Fig. 4. Antitumor effects of therapeutic HB1.F3-CD (F3-CD) cells in the presence of 5-fluorocytosine (5-FC) in vivo. (A) Differences in mouse size in representative animals indicate the low toxicity of 5-fluorocytosine (5-FC) administration (upper) in comparison with the serious weight loss caused by 5-fluorouracil (5-FU) treatment (down). (B) There was no significant difference in weight between animals treated with 5-FC and animals treated with phosphate-buffered saline. Animals treated with 5-fluorouracil showed significant weight loss compared with animals treated with 5-FC. PBS, phosphate-buffered saline. *P<0.01, Mann-Whitney U-test.
ed with 5-FU showed significant weight loss in comparison to animals treated with 5-FC (Fig. 5). Animals treated with 5-FU also exhibited bloody stools.

DISCUSSION

In this study, we tested the hypothesis that NSCs expressing a therapeutic gene would have positive therapeutic effects on HNSCC. We chose the human F3 NSC cell line, because this human stem cell line is well-established and well-characterized [8-15]. The F3 human NSC line was immortalized using v-myc [8,10,11] and is an ideal vehicle for the delivery of suicide genes or immunomodulatory genes to tumor targets, including primary brain tumors and brain metastases [22,23]. The present study found no abnormalities caused by treatment with F3-CD cells; however, tumor formation must be considered a risk, due to the presence of the v-myc oncogene in the F3 human NSCs. In this study, no sign of local or systemic toxicity was observed in the F3-CD treated groups, although the therapeutic effects were assessed 3 weeks after NSC injection.

The in vitro and in vivo studies in this report show for the first time the ability of NSCs to target HNSCC, indicating that tumor tropism of NSCs is not limited to brain tumors. A possible mechanism of preferential stem cell homing and engraftment into the tumor mass could be attributed to the necessity for tumor stroma formation during the process of tumor growth, which includes tissue remodeling and involves high levels of stem cell proliferation [24]. Migratory properties must be further evaluated to determine tumor type specificity and to identify signaling molecules involved in this process, because of its relevance to potential therapeutic applications. It has previously been reported that epidermal growth factor, platelet-derived growth factor, SCF/c-Kit, stromal cell derived factor-1/CXCR4, vascular endothelial growth factor (VEGF), VEGF receptor 1 (VEGFR1), and VEGFR2 may play roles in these intrinsic tumor-specific migration capabilities and interactions [25,26].

After confirmation of the tropism of NSCs for head and neck squamous carcinoma cells, we tested their therapeutic potential using the CD enzyme/5-FC prodrug system. CD is a bacterial enzyme that converts the non-toxic prodrug 5-FC into the cytotoxic drug 5-FU, a nucleotide analog that disrupts DNA synthesis in proliferating cells [27]. Because mammalian cells do not express significant amounts of CD, as shown in the present study, 5-FC is not toxic at concentrations that result in strong antimicrobial activity. Thus, tumor cells transfected with the *E. coli* CD gene become selectively sensitive to the toxic effects of 5-FC. For example, expression of *E. coli* CD in glioma cells confers lethal sensitivity to systemic administration of 5-FC [28]. Furthermore, the enzyme/prodrug system also has a bystander effect [29], shown by the death of unmodified tumor cells adjacent to genetically modified cells. NSCs engineered to express a suicide gene like CD are a particularly beneficial therapeutic choice because they can generate agents that both kill tumor cells and result in self-elimination upon initiation of cell division in vivo.

Potential cancer therapies involving selective activation of prodrugs in tumor tissues by exogenous enzymes have used several distinct mechanisms, including gene directed enzyme prodrug therapy, virus-directed enzyme prodrug therapy, and antibody-directed enzyme prodrug therapy [30]. The cell-directed enzyme prodrug therapy using NSCs described in this report is potentially more flexible than previous methods, because of the tumor-tropic capacity of NSCs. Because of an impressive bystander effect, as little as 2% of the tumor mass containing CD-expressing cells may generate significant oncolysis [29]. This unique property increases the likelihood of achieving therapeutic efficacy. For clinical application of cell-directed enzyme prodrug therapy, the interval between enzyme and prodrug administration should be optimized so that prodrug delivery occurs only after NSCs localize to tumor site to avoid systemic toxicity.

Although a significant reduction in tumor volume was induced by cell-based therapy in this study, none of the animals remained tumor-free or was cured in this experimental setting. It is generally acknowledged that a successful long-term effective therapy or curative approach would require a combination of multiple treatment strategies. In our approach, the 5-FU produced at the site of tumor formation would be expected to eliminate the rapidly proliferating tumor cell population, based on the mechanism of action of 5-FU [4]. However, quiescent and non-dividing tumor cells present within the tumor mass may be able to withstand the toxicity. Our future studies will be directed towards optimization of protocols for dosage and timing of the therapy to achieve maximum suppression of tumor growth. As the therapeutic benefit from one time drug delivery may be short-lived as the tumor regenerates, additional cycles of F3-CD and 5-FC therapy could be given to eradicate proliferating cancer cells not removed by the first wave of therapy. Alternatively, NSCs could be engineered to express other potentially beneficial therapeutic genes (e.g., differentiating agents, immune enhancing agents, apoptosis-promoting agents, antiangiogenic agents), which could be used sequentially or in combination with F3-CD treatment.

In the clinical setting, NSC therapy could be used in conjunction with standard therapies in the near future. Particularly in the case of recurrence with tumor dissemination, NSCs could be injected into veins to target residual invading and disseminating tumor cells. Furthermore, based on our study, the same approach could be exploited using other sources of stem cells and they could be engineered to deliver other antitumor agents for cancer therapies.

In conclusion, this study indicates that NSCs have migratory capacity and exhibit tropism for HNSCC. Furthermore, these cells can be genetically modified ex vivo to express genes that
have therapeutic efficacy against HNSCC. These results suggest the potential utility of NSCs as a targeted therapeutic delivery vehicle for the treatment of HNSCC.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

This work was supported by the Korea Research Foundation Grant funded by the Korean Government (NRF-2008-313-E00393) and by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2011-0014024).

REFERENCES

1. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004 May;350(19):1937-44.

2. Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol. 2004 Jun;22(11):2214-32.

3. Kucerova L, Altanerova V, Matuskova M, Tyciakova S, Altaner C. Adipose tissue-derived human mesenchymal stem cells mediated prodrug gene therapy. Cancer Res. 2007 Jun;67(13):6304-13.

4. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003 May;3(5):330-8.

5. Hamada H, Kobune M, Nakamura K, Kawano Y, Kato K, Honmou O, et al. Mesenchymal stem cells (MSC) as therapeutic cytoreagents for preservation with fluorouracil: current and future approaches to fluorouracil drug cancer gene therapy. Cancer Res. 2002 Feb;62(3):773-80.

6. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A. 2000 Nov;97(23):12846-51.

7. Aboody KS, Najbauer J, Schmidt NO, Yang W, Wu JK, Zhuge Y, et al. Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro Oncol. 2006 Apr;8(2):119-26.

8. Kim SU. Human neural stem cells genetically modified for brain repair. Neuroreport. 2002 Aug;13(11):1447-52.

9. Ourednik V, Ourednik J, Flax JD, Zawada WM, Hutt C, Yang W, et al. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer. 2006 Sep;121(4):555-62.

10. Curcio CA, Cook EH, Millican CE, Williams BR. Axons of human embryonic retinal ganglion cells can regenerate across the optic nerve and reinnervate visual cortex in adult rhesus macaques. J Comp Neurol. 1989 May 8;281(2):227-40.

11. Chu K, Kim M, Chae SH, Jeong SW, Kang KS, Jung KH, et al. Distribution and in situ proliferation patterns of intravenously injected immortalized human neural stem-like cells in rats with focal cerebral ischemia. Neurosci Lett. 2004 Jun;343(2):129-33.

12. Schmidt NO, Przybeck W, Yang W, Ziu M, Teng Y, Kim SU, et al. Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. Neoplasia. 2005 Jun;7(6):623-9.

13. Jeong SW, Chu K, Jung KH, Kim SU, Kim M, Roh JK. Human neural stem cell transplantation promotes functional recovery in rats with experimental intracerebral hemorrhage. Stroke. 2003 Sep;34(9):2258-63.

14. Ko JM, Kim M, Chae SH, Jeong SW, Kang KS, Jung KH, et al. Distribution and in situ proliferation patterns of intravenously injected immortalized human neural stem-like cells in rats with focal cerebral ischemia. Neurosci Lett. 2004 Jun;343(2):129-33.

15. Chu K, Kim M, Jeong SW, Kim SU, Yoon BW. Human neural stem cells can migrate, differentiate, and integrate after intravenous transplantation in adult rats with transient forebrain ischemia. Neurosci Lett. 2003 Jun;343(2):129-33.

16. Ferrucci JT. Advances in abdominal MR imaging. Radiographics. 1998 Nov-Dec;18(6):1569-86.

17. Frank JA, Miller BR, Arbab AS, Zywicke HA, Jordan EK, Lewis BK, et al. Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology. 2003 Aug;228(2):480-7.

18. Bulte JW, Arbab AS, Douglas T, Frank JA. Preparation of magnetically labeled cells for cell tracking by magnetic resonance imaging. Methods Enzymol. 2004;386:275-99.

19. Kalish H, Arbab AS, Miller BR, Lewis BK, Zywicke HA, Bulte JW, et al. Combination of transfection agents and magnetic resonance contrast agents for cellular imaging: relationship between relativity, electrostatic forces, and chemical composition. Magn Reson Med. 2003 Aug;50(2):275-82.

20. Arbab AS, Bashaw LA, Miller BR, Jordan EK, Lewis BK, Kalish H, et al. Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology. 2003 Dec;229(3):838-46.

21. Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, Brunetti M, et al. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer. 2000 Aug;87(4):595-600.

22. Shimato S, Natsune A, Takeuchi H, Wakabayashi T, Fujii M, Ito M, et al. Human neural stem cells target and deliver therapeutic gene to experimental leptomeningeal melanoblastoma. Gene Ther. 2007 Aug;14(15):1132-42.

23. Aboody KS, Bush RA, Garcia E, Metz MZ, Najbauer J, Justus KA, et al. Development of a tumor-selective approach to treat metastatic cancer. PLoS One. 2006 Dec;1:e23.

24. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Feb 10;100(1):57-70.

25. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, et al. Human bone marrow-derived mesenchymal stem cells mediated prodrug gene therapy is effective for experimental human glioblastomas. Cancer Res. 2006 Sep;66(18):9030-6.

26. Hendrie LH, O’Donnell TF, O’Connell MJ, Landers MD, Clifton IA. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorouracil: a negative selection system. Proc Natl Acad Sci U S A. 1992 Jan;89(1):33-7.

27. Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res. 2002 Feb;62(3):773-80.

28. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells
transduced with the cytosine deaminase gene: significant antitumor
effects when only a small percentage of tumor cells express cytosine
deaminase. Proc Natl Acad Sci U S A. 1994 Aug;91(17):8302-6.

30. Xu G, McLeod HL. Strategies for enzyme/prodrug cancer therapy.
Clin Cancer Res. 2001 Nov;7(11):3314-24.